← Back to Search

Other

NANT Squamous Cell Carcinoma (SCC) Vaccine for Squamous Cell Carcinoma

Phase 1 & 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal design.

Eligible Conditions
  • Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.
Duration of response by RECIST and irRC
Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NANT Squamous Cell Carcinoma (SCC) VaccineExperimental Treatment21 Interventions
Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fluorouracil
FDA approved
Leucovorin
FDA approved
SBRT
2014
Completed Phase 2
~1060
ETBX-011
2017
Completed Phase 2
~10
Cisplatin
FDA approved
Necitumumab
FDA approved
Avelumab
FDA approved
Capecitabine
FDA approved
Cyclophosphamide
FDA approved
Bevacizumab
FDA approved
GI-4000
Not yet FDA approved
Inbakicept
Not yet FDA approved
Cetuximab
FDA approved
Paclitaxel
FDA approved

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
63 Previous Clinical Trials
5,071 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Apr 2025